University of Leicester
Browse
Efficacy of iGlarLixi in adults with type 2 diabetes inadequately controlled (glycated haemoglobin = 8%, = 64 mmolmol) on two oral antidiabetes drugs Post hoc analysis of the LixiLan-O randomized trial.pdf (821.72 kB)

Efficacy of iGlarLixi in adults with type 2 diabetes inadequately controlled (glycated haemoglobin >= 8%, >= 64 mmol/mol) on two oral antidiabetes drugs: Post hoc analysis of the LixiLan-O randomized trial

Download (821.72 kB)
journal contribution
posted on 2023-12-11, 12:11 authored by Melanie J Davies, Julio Rosenstock, Amar Ali, David Russell-Jones, Elisabeth Souhami, Karen Palmer, Chen Ji, Elisabeth Niemoeller, Neil Skolnik
Aims: To assess the efficacy and safety of iGlarLixi (the titratable fixed-ratio combination of insulin glargine 100 U/mL [iGlar] plus lixisenatide [Lixi]), in adults with type 2 diabetes (T2D) with glycated haemoglobin (HbA1c) levels ≥8% (≥64 mmol/mol). Materials and methods: The LixiLan-O study (NCT02058147) compared iGlarLixi with iGlar or Lixi in adults with T2D inadequately controlled on metformin ± a second oral antidiabetes drug (OAD). This exploratory analysis evaluated the LixiLan-O subgroup of participants with baseline HbA1c levels of ≥8% (≥64 mmol/mol) who were receiving metformin plus a second OAD at screening. Results: The mean diabetes duration was 10.0 years, and the mean duration of second OAD use was 4.5 years. iGlarLixi demonstrated greater mean reductions from baseline in HbA1c and 2-hour postprandial glucose (PPG) compared with iGlar or Lixi (HbA1c −1.9% vs. −1.6% or −1.0% [−20 vs. −17 or −10 mmol/mol; 2-hour PPG −7.2 vs. −4.6 or −5.5 mmol/L). Greater proportions of participants achieved HbA1c <7% (<53 mmol/mol) with iGlarLixi versus iGlar or Lixi (67% vs. 51% or 18%), and the composite endpoints of HbA1c <7% (<53 mmol/mol) with no body weight gain (36% vs. 19% or 16%), and HbA1c <7% (<53 mmol/mol) with no body weight gain and no documented symptomatic hypoglycaemia (plasma glucose ≤3.9 mmol/L; 28% vs. 15% or 15%). The incidence rates of documented symptomatic hypoglycaemia were 29.0%, 27.9% and 12.1% for iGlarLixi, iGlar and Lixi, respectively. Conclusions: Adults with T2D and HbA1c ≥64 mmol/mol (≥8%) despite two OADs at screening achieved better glycaemic control with iGlarLixi versus iGlar or Lixi, without increased risk of hypoglycaemia versus iGlar.

History

Citation

Davies MJ, Rosenstock J, Ali A, et al.Efficacy of iGlarLixi in adults with type 2 diabetesinadequately controlled (glycated haemoglobin≥8%,≥64 mmol/mol) on two oral antidiabetes drugs: Post hocanalysis of the LixiLan-O randomized trial.Diabetes ObesMetab. 2022;24(1):34-41. doi:10.1111/dom.14543DAVIESET AL.41

Author affiliation

Diabetes Research Centre, University of Leicester

Version

  • VoR (Version of Record)

Published in

Diabetes, Obesity and Metabolism: a journal of pharmacology and therapeutics

Volume

24

Issue

1

Pagination

34-41

Publisher

Wiley

issn

1462-8902

eissn

1463-1326

Acceptance date

2021-08-31

Copyright date

2021

Available date

2023-12-11

Language

English